Navigation Links
Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board
Date:2/26/2013

ROCKVILLE, Md., Feb. 26, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that Brad Spellberg , M.D., joined the Company's Scientific Advisory Board. Dr. Spellberg is an infectious disease specialist whose NIH-funded laboratory studies highly drug-resistant infections in an effort to develop vaccines and immune therapies to prevent and treat them. He has also worked closely with the Infectious Diseases Society of America (IDSA) to focus attention on the rising public health crisis caused by increasing antibiotic resistance and decreasing new antibiotic development.

Dr. Spellberg is an Associate Professor of Medicine, David Geffen School of Medicine in the Division of General Internal Medicine at Harbor-UCLA Medical Center, and Associate Program Director for Internal Medicine Residency Training Program, Harbor-UCLA Medical Center and LA BioMed. His research regarding new drug development for the prevention and treatment of infectious diseases became the foundation for the IDSA's white paper, "Bad Bugs, No Drugs," and has been cited extensively in medical publications and on Capitol Hill. He is a Fellow in the IDSA and has served as Co-Chair of the IDSA's Antimicrobial Availability Task Force (AATF). As a member of the AATF, he has first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development. Dr. Spellberg is also the author of Rising Plague: The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them, which he wrote to inform and educate the public about the crisis in antibiotic resistant infections and lack of antibiotic development.

"As we expand our infectious disease pipeline, we are very pleased to welcome Dr. Spellberg to our Scientific Advisory
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
2. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
3. Frost & Sullivan: Asia Pacific Infectious Disease Diagnostics Market Grows as Economies Boom and Countries Become Image Conscious
4. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
5. Infectious Disease Prevalence and New Strains Appearing Each Year Makes a Watertight Case for Clinical Laboratory Testing, Finds Frost & Sullivan
6. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
7. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
8. US Lab Deployed to Boost Mexicos Response to Outbreaks of Infectious Disease
9. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
10. Modeling Alzheimers disease using iPSCs
11. GUARDaHEART Foundation Hosts Love Your Heart Day Event in Celebration of Heart Disease Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
(Date:7/24/2014)...   Cypher Genomics, Inc., the genome ... Adam Simpson as president and chief operating ... annotation and interpretation of individual human genomes for ... technology has the potential to play a transformative ... optimizing therapeutic approaches and reducing adverse drug reactions," ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... BUFFALO, N.Y., April 19, 2011 Today, H. ... CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused ... Kinase (FAK) inhibitors for cancer, provided a company ... leaders at the Celebration of Innovation Showcase 2011 ...
... April 19, 2011 Practice Fusion, the leading EHR ... the addition of Paul Willard as Vice President of ... Development. The news of the expanded executive team follows ... the Electronic Health Record system , led by ...
... Tissue Genesis, Inc., an emerging leader in adult ... has begun clinical trials for peripheral vascular disease (PVD) ... at the University of Louisville Hospital.  Tissue Genesis is ... patient,s own adipose-derived adult stem cells (ASCs) prepared at ...
Cached Biology Technology:CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 3CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 4Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director 2Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director 3Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director 4Tissue Genesis Begins FDA-Approved Clinical Trial 2Tissue Genesis Begins FDA-Approved Clinical Trial 3
(Date:7/25/2014)... PITTSBURGH -- The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic ... the correct initial surgery by 30 percent, according ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Acoustic disturbance has different effects on different species ... the Universities of Bristol and Exeter which tested ... sooner to a flying seagull predator model when ... observed in European minnows. , Lead author ... Sciences said: "Noise levels in many aquatic environments ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... , A group of Japanese researchers, who publish their findings ... Biomimetics , have succeeded in building a fully functional replica ... they have filmed their model butterfly flying. Among the ... wing area is very large relative to their body mass. ...
... to minimize the use of chemical herbicides need creative solutions ... research at the University of Illinois on Canada thistle, Sudangrass ... smother crop. "Sudangrass get very tall. It outcompetes the ... occur in the thistle," said U of I weed scientist ...
... NC Social status in paper wasps is established earlier ... month in the journal PLoS ONE . While ... appearance and are fixed from birth, paper wasp society is ... can climb the social ladder and become a queen. Now, ...
Cached Biology News:Sudangrass recommended to combat Canada thistle 2Sudangrass recommended to combat Canada thistle 3The making of a queen: Road to royalty begins early in paper wasps 2
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... crosslinked to protein G-agarose beads which can ... heart mitochondria. Also included are 2 mg ... ,The pyruvate dehydrogenase complex (PDH) immunocapture kit ... of tissue. This facilitates the subsequent analysis ...
... PULSin may be superior to transfection in ... transfection, with PULSin you can study lethal ... course of proteins in cells. Likewise, delivery ... than traditional RNA interference experiments. ,With ...
Biology Products: